|
|
|
Intra cellular Therapies Inc (NASDAQ: ITCI) |
|
|
|
| |
Intra cellular Therapies Inc Outlook |
On October 30 2024 the Intra cellular Therapies Inc provided following guidance
Intra-Cellular Therapies Inc. has recently released its financial results for the third quarter of 2024, along with a corporate update that signals a positive trajectory for the company. Notably, the company has raised its sales guidance for Caplyta for the year 2024, indicating optimism about its market performance, although specific figures regarding the adjusted guidance were not disclosed in the announcement.
During the third quarter of 2024, Intra-Cellular Therapies reported impressive net product sales for Caplyta, totaling $175.2 million. This marks a remarkable 39% increase compared to the $125.8 million reported during the same quarter in 2023, highlighting the growing demand and acceptance of the product in the market.,
|
On August 7 2024 the Intra cellular Therapies Inc provided following guidance
Intra-Cellular Therapies Inc. has released its financial results for the second quarter of 2024, revealing significant growth and a positive outlook for its flagship product, CAPLYTA. The company has announced an upward revision in its sales guidance for CAPLYTA for the year 2024, showcasing confidence in the product’s continued market performance. While the exact figures for the updated sales projections have not been disclosed, the implications suggest that the company anticipates robust sales growth.
During the second quarter of 2024, CAPLYTA generated net product sales of $161.3 million, a substantial increase from $110.1 million during the same quarter of 2023, marking a remarkable 46% growth year-over-year. This impressive sales surge highlights CAPLYTA's expanding market penetration and the increasing demand for its therapeutic benefits.
Intra-Cellular Therapies' decision to raise its sales guidance reflects a strategic response to this positive momentum. The company remains focused on advancing its corporate objectives and enhancing shareholder value, as evidenced by its recent financial performance and optimistic market outlook for the remainder of 2024.,
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
